The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation

Health Technol Assess. 2002;6(14):1-269.

Authors

R Lewis¹, A-M Bagnall, S King, N Woolacott, C Forbes, L Shirran, S Duffy, J Kleijnen, G ter Riet, R Riemsma

Affiliation

¹ NHS Centre for Reviews and Dissemination, University of York, UK.

PMID: 12583816

No abstract available

Publication types

Clinical Trial
Randomized Controlled Trial
Review
Systematic Review

MeSH terms

Antineoplastic Agents, Phytogenic* / adverse effects
Antineoplastic Agents, Phytogenic* / economics
Antineoplastic Agents, Phytogenic* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Cost-Benefit Analysis
Female
Humans
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic
Treatment Outcome
Vinblastine* / adverse effects
Vinblastine* / analogs & derivatives*
Vinblastine* / economics
Vinblastine* / therapeutic use
Vinorelbine

Substances

Antineoplastic Agents, Phytogenic
Vinblastine
Vinorelbine